Home » Pharmaceutical Articles » 91% Of The Total Promotional Spend In The US And The Five EU Countries Was Spent On Detailing Physicians
91% Of The Total Promotional Spend In The US And The Five EU Countries Was Spent On Detailing Physicians
Explore trends and developments in key issues, including patent expiry and OTC status, and how they impact the key antihistamine and nasal corticosteroid classes
/24-7PressRelease.com/ -- Research and Markets (http://www.researchandmarkets.com/reports/c8102) has announced the addition of Commercial and Stakeholder Perspectives: Allergic Rhinitis - Is There Life After Claritin? to their offering
Introduction
Commercial and Stakeholder Perspectives: Allergic Rhinitis, explores trends and developments in key issues, including patent expiry and OTC status, and how they impact the key antihistamine and nasal corticosteroid classes. Major brands are profiled and benchmarked against both product and company strengths, and country-specific threats within each market are outlined.
Scope
Patient potential and overview of the allergic rhinitis market, including key events impacting the antihistamine and nasal corticosteroid classes
Global sales forecasts to 2014, including country-specific forecasts for the US, Japan, France, Germany, Italy, Spain and the UK
Profiles and benchmarking of brands against product and company strengths, and an outline of country-specific threats within each market
Analysis of physician prescribing patterns, and case studies presenting the outcome of regulatory changes, generic erosion, and Rx to OTC switching
Highlights
In 2003, 91% of the total promotional spend in the US and the five EU countries was spent on detailing physicians. The physician specialists prescribing treatments for allergic rhinitis are numerous and wide ranging in the US, Germany and Japan. However, the other EU countries are heavily skewed towards PCP treatment of allergic rhinitis.
The patent expiry of Claritin (loratadine) has seen wide ranging country variances in both revenue and prescription volume sales adjustments for the brand, molecule and class. Germany, the US and the UK experienced the largest reduction in brand revenue sales values, whereas generic erosion was minimal in Japan and the remaining EU countries.
Careful consideration of the impact of patent expiry on Claritin provides several pointers as to how other antihistamines may be impacted by similar events. The 2007 Zyrtec (cetirizine) patent expiry, and a favorable outcome for the generics companies in the Allegra (fexofenadine) patent legislation, are two such events.
Reasons to Purchase
Effectively target the key stakeholders most likely to prescribe your brand and explore ways of influencing other prescribers
Examine the impact of future patent expiries in each of the seven country markets
Assess company, clinical and country issues with key brand benchmarking and environmental opportunities and threats
TABLE OF CONTENTS
CHAPTER 1 EXECUTIVE SUMMARY 3
CHAPTER 2 PATIENT POTENTIAL 13
CHAPTER 3 GLOBAL MARKET DEFINITION AND OVERVIEW 26
CHAPTER 4 KEY BRAND ASSESSMENT AND FORECASTING ASSUMPTIONS 32
CHAPTER 5 ENVIRONMENTAL ASSESSMENTS 76
CHAPTER 6 CASE STUDIES 88
Case study one – Impact of regulatory change on patent protection for allergic rhinitis treatment 88
Case study two – Variation in degree of country-specific generic erosion for antihistamines and corticosteroids 94
For more information visit http://www.researchandmarkets.com/reports/c8102
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com |
|
|
Press Release Contact Information:
Patrick Good
Research and Markets
Press Officer
Voice: 00353 1 4151243
Fax: 00353 1 4100980
|
|
|
|
|
| PHARMACEUTICAL ARCHIVE SEARCH |
|
|
| |
| SUBMIT PHARMACEUTICAL NEWS |
|
|
| |
|
|
Advertise With Us |
About Us |
Contact Us